Munich, January 18, 2017 – German business law firm Gütt Olk Feldhaus has advised Eternygen GmbH, a Berlin-based metabolic diseases company, on a EUR 8 million Series A funding round. Epidarex Capital led the round, and Evotec AG participated together with a consortium of investors including VC Fonds Technologie, managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices. Further financial details are not disclosed.
Eternygen is a Berlin, Germany based Biotech Company founded in June 2012 and focussing on the research, development and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The founding team consists of renowned scientists from leading German universities and academic institutes as well as serial entrepreneurs from the venture and industry community. Eternygen is supported by a network of senior industry experts and contract research organizations. Eternygen will use the proceeds of the Series A funding to accelerate its small molecule NaCT inhibitors towards the selection of a pre-clinical lead candidate.
Legal advisor to Eternygen:
Gütt Olk Feldhaus, Munich: Dr. Heiner Feldhaus (Partner), Attila Oldag (Partner), Dr. Daniel Holzmann (Counsel), Nicole Beyersdorfer (Senior Associate).
About Gütt Olk Feldhaus:
Gütt Olk Feldhaus is a law firm founded by experienced lawyers from leading international law firms. All partners of the Munich-based law firm previously worked for many years at Freshfields Bruckhaus Deringer, Hengeler Mueller, Milbank Tweed Hadley & McCloy and/or Latham & Watkins, respectively. The key areas of expertise of Gütt Olk Feldhaus are M&A, private equity, finance and corporate with a particular focus on transactions and cross border aspects.
Contact:
Dr. Heiner Feldhaus
Partner
Tel. +49 89 24 22 41 130
Heiner.Feldhaus@gof-partner.com